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Abstract
Background: Multiple sclerosis (MS) is a multifactorial disease with a genetic basis. The strongest associations with the
disease lie in the Human Leukocyte Antigen (HLA) region. However, except for the DRB1*15:01 allele, the main risk factor
associated to MS so far, no consistent effect has been described for any other variant. One example is HLA-DRB1*03:01, with
a heterogeneous effect across populations and studies. We postulate that those discrepancies could be due to differences in
the diverse haplotypes bearing that allele. Thus, we aimed at studying the association of DRB1*03:01 with MS susceptibility
considering this allele globally and stratified by haplotypes. We also evaluated the association with the presence of
oligoclonal IgM bands against myelin lipids (OCMB) in cerebrospinal fluid.
Methods: Genotyping of HLA-B, -DRB1 and -DQA1 was performed in 1068 MS patients and 624 ethnically matched healthy
controls. One hundred and thirty-nine MS patients were classified according to the presence (M+, 58 patients)/absence (M2,
81 patients) of OCMB. Comparisons between groups (MS patients vs. controls and M+ vs. M2) were performed with the chi-
square test or the Fisher exact test.
Results: Association of DRB1*03:01 with MS susceptibility was observed but with different haplotypic contribution, being
the ancestral haplotype (AH) 18.2 the one causing the highest risk. Comparisons between M+,M 2 and controls showed
that the AH 18.2 was affecting only M+ individuals, conferring a risk similar to that caused by DRB1*15:01.
Conclusions: The diverse DRB1*03:01-containing haplotypes contribute with different risk to MS susceptibility. The AH 18.2
causes the highest risk and affects only to individuals showing OCMB.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease which
affects the central nervous system and it is characterized by myelin
destruction, axonal degeneration and progressive neurological
dysfunction. MS shows a complex etiology, which comprises the
interplay of genetic and environmental factors. A clear and well
established influence of the Human Leukocyte Antigen (HLA)
allele DRB1*15:01 has been shown in almost all the populations
studied, pointing to this allele as the main risk factor contributing
to disease susceptibility. However, it is known that other HLA
genetic variants influence disease development, but the additional
genetic contribution of this region is far to be understood.
Although the special characteristics of this region and the very
probable existence of epistatic interactions between different HLA
risk alleles [1,2] hampers the study of this region, small steps can
be taken trying to elucidate this problem. A relevant issue to deal
with is the one concerning DRB1*03:01. This allele has been
consistently associated with high MS risk in Sardinia [3,4], but
heterogeneous data exist regarding the effect of DRB1*03:01 in
other populations [1,3,5,6,7,8].
HLA peculiarities include the existence of specific allele
combinations over large regions which have been conserved
across generations and conform the so-called ancestral haplotypes
(AH). The DRB1*03:01 allele is present in two AH: 18.2 and 8.1,
i.e., it can be found in two different haplo-specific contexts.
Besides, this allele can be found within non-specific allelic
combinations, including partially-conserved 18.2 and 8.1 AH
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frequency of those DRB1*03:01-containing haplotypes varies
greatly depending on the geographical location. Thus, in
populations of Northern Europe DRB1*03:01 appears preferen-
tially in the AH 8.1, but it does in the AH 18.2 in Sardinia.
According to this, differences in the MS risk conferred by those
haplotypes could be underlying the heterogeneity observed in the
previously published studies focused in the DRB1*03:01 allele.
In the Spanish population, our research group described an
association between MS susceptibility and one polymorphism
located in the promoter of the tumor necrosis factor-alpha (TNF)
gene, rs1800750 (TNF -376) [9,10]. Later, association with TNF
rs1800750 was also found in a subgroup of Spanish MS patients
characterized by the presence of oligoclonal IgM bands against
myelin lipids (OCMB) restricted to cerebrospinal fluid (CSF) [11],
which has been described as conditioning an aggressive MS
course. In both cases, the susceptibility allele was rs1800750_A,
which is almost exclusively present on the AH 18.2. Of note, in
Spain, like in other populations of South Europe, the three subsets
of DRB1*03:01-bearing haplotypes (AH 18.2, AH 8.1 and non-
conserved ones) appear approximately at a similar frequency. This
situation enables us to investigate whether those subsets contribute
in a similar manner to MS susceptibility.
In the present work, we aimed at studying the role of
DRB1*03:01 in relation to MS risk and production of oligoclonal
IgM against myelin lipids, with special attention to the putatively
different contribution of the different haplotypes bearing that
allele.
Methods
Ethics Statement
This study was approved by the ethical committees of the
participant hospitals (Comite ´E ´tico de Investigacio ´n Clı ´nica
(CEIC) del Hospital Clı ´nico San Carlos, CEIC del Hospital
Ramo ´n y Cajal and CEIC del Hospital Universitario Carlos
Haya). Samples were obtained after obtaining written informed
consent.
Subjects
We studied 929 MS patients diagnosed following the Poser
criteria [12] and 624 ethnically matched individuals without
autoimmune diseases as controls. All individuals were Spanish of
Caucasian ancestry. Samples were consecutively recruited at both
Hospital Clı ´nico San Carlos (Madrid) and Hospital Universitario
Carlos Haya (Ma ´laga). Population stratification is not present in
our samples, since reduced genomic control inflation factor was
observed after genotyping more than 200,000 SNPs.
To study the influence of DRB1*03:01 on the presence of
OCMB, we studied 139 independent MS patients recruited at the
Hospital Ramo ´n y Cajal (Madrid). All these patients showed a
relapsing-remitting disease; a total of 58 patients showed OCMB
in CSF (M+ group) and 81 lacked them (M2 group).
HLA Genotyping
DNA was extracted from fresh peripheral blood leukocytes by a
‘‘salting out’’ procedure. HLA-B,- DRB1 and -DQB1 were typed by
polymerase chain reaction-sequence-specific oligonucleotide
(PCR-SSO) following manufacturer recommendations (Tepnel
Lifecodes Corp., Stamford, CT, USA). The presence of the
DRB1*15:01 allele was also tested by TaqMan technology using
the highly correlated SNP rs3135388 (Applied Biosystems Inc.,
Foster City, CA, USA).
AH 18.2 and 8.1 were assessed by genotyping of HLA-B,- DRB1
and -DQB1. Additionally, the TNF singe nucleotide polymor-
phisms 2308 (rs1800629) and 2376 (rs1800750) and the
microsatellites TNFa and TNFb were also ascertained. TNF
polymorphisms were typed as previously described [9,13].
IgM detection
Detection of the lipid-specific oligoclonal IgM bands was
performed by isoelectric focusing and immunoblotting as previ-
ously described [14].
Statistical analysis
HLA haplotypes were estimated using the EM (Expectation-
Maximization) algorithm implemented in the Arlequin software.
Comparisons between groups were performed with the chi-
square test or the Fisher’s exact test when proper (expected values
below 5) using the statistical package EpiInfo v5.00 (CDC, Atlanta,
USA). Heterogeneity between groups was evaluated with Review
Manager (RevMan) 5.0 software (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008).
Results
No heterogeneity was observed between samples collected in
Madrid and Ma ´laga, therefore, pooled data are presented.
The frequency of the different DRB1*03:01-containing haplo-
types in MS patients and in controls is shown in Table 1. Patients
were stratified according to the presence/absence of the
DRB1*15:01 allele risk, but no differences were found between
those two MS groups when DRB1*03:01 data were analysed;
therefore, all MS patients were combined (column ‘‘total’’ of
Table 1) for case-control comparisons.
First, we investigated the possible role of DRB1*03:01 in MS
susceptibility and we observed a highly significant effect:
OR=1.52, 95% CI 1.23–1.88, p=7.1*10
25. Since AH 18.2
and AH 8.1 appear at a similar frequency in the Spanish controls
(around 30% of all DRB1*03:01), we could evaluate the possible
different contribution of those two haplotypes in disease risk. We
started with AH 18.2 analysis, which showed a significant
association and higher risk than when considering all
DRB1*03:01-bearing haplotypes: OR=1.94, 95% CI 1.36–2.78,
p=1.3*10
24 (Table 1). Due to its key role in MS risk, 18.2
haplotypes were removed from subsequent analysis in order to
ascertain a putative effect of other AHs. We examined the
influence of AH 8.1, but a significant result was not obtained.
Similarly, no association was found when considering the non-
conserved DRB1*03:01 haplotypes. However, since statistical
power limitations could be affecting these results, we combined
AH 8.1 and non-conserved DRB1*03:01 haplotypes data (given
their lack of heterogeneity: p=0.76; I
2=0%) and then a
significant result emerged (p=0.027, OR=1.32, 95% CI 1.02–
1.70), pointing to a contribution of DRB1*03:01 carrying
haplotypes others than AH 18.2 to MS risk, as seems to be
deduced from the existing literature. To obtain a more accurate
estimation of the specific effect caused by AH 18.2, we excluded
AH 8.1 and non-conserved haplotypes from the initial analysis and
we obtained an OR=2.00, 95% CI 1.40–2.87 (p=6.4*10
25). Of
note, heterogeneity was detected between AH 18.2 and the
remaining DRB1*03:01 haplotypes: p=0.05, I
2=74%, supporting
the mentioned stronger effect on MS risk of this AH.
Next, we studied the involvement of DRB1*03:01 in the
presence of OCMB in MS patients (Table 2). No differences
were observed between patients stratified by the presence (M+
group)/absence (M2 group) of OCMB when considering all
DRB1*03:01, IgM Bands and Multiple Sclerosis Risk
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after individual analysis of the different DRB1*03:01 haplotypes.
The previously observed effect for AH 18.2 was exclusively present
when studying M+ patients (p=0.0088 M+ vs. M2;
p=0.0055 M+ vs. controls). No differences seemed to exist
between M+ and M2 for DRB1*03:01 haplotypes others than
the AH 18.2.
Since the two groups of MS patients studied (Table 1 and
Table 2) constitute independent samples, we combined their data
to increase statistical power and a significant association was
observed when considering the DRB1*03:01 non-conserved
haplotypes: p=0.037, OR=1.39, 95% CI 1.01–1.93.
We also evaluated the effect of the DRB1*15:01 allele in M+
and M2 patients. A similar risk was observed in both groups of
patients, also similar to the risk observed when considering the
overall MS patients: OR=2.56, 95% CI 1.99–3.29 (allelic risk).
This effect is similar to the one caused by the AH 18.2 in M+
patients (heterogeneity: p=0.69; I
2=0%) and significantly higher
to the risk conferred by the non-conserved DRB1*03:01
haplotypes (heterogeneity: p=0.003; I
2=89%).
Discussion
Last years have witnessed an increasing number of genetic
regions involved in MS susceptibility; however, the strongest
association signals with disease risk remain in the long-known
HLA region. Nevertheless, except for the well-established effect of
HLA-DRB1*15:01, genetic influence at this region remains elusive.
We studied the risk conferred by the different DRB1*03:01-
containing haplotypes (AH 18.2, AH 8.1 and non-conserved
haplotypes) in relation to MS susceptibility and, specifically, to the
presence of intrathecal IgM against myelin lipids restricted to CSF
in MS patients. Our results indicate that patients bearing the AH
18.2 show an increased risk to produce intrathecal IgM
(OR=2.98 95% CI 1.36–6.39) and this effect seems to be
independent of the presence of HLA-DRB1*15:01. The strong
Table 1. Frequency of the different DRB1*03:01-containing haplotypes in DRB1*15:01 positive (+) and negative (2) multiple
sclerosis (MS) patients and in controls; and case-control study for the total MS patients.
MS PATIENTS
CONTROLS MS PATIENTS vs. CONTROLS DRB1*15:01 (2) DRB1*15:01 (+) Total
n % n % n % n % p OR (95% CI)
DRB1*03:01
All 233 19.5 57 17.2 290 19.0 167 13.4 7.1*10
25 1.52 (1.23–1.88)
AH 18.2 88 7.4 24 7.2 112 7.3 49 3.9 1.3*10
24 1.94 (1.36–2.78)
AH 8.1 60 5.03 17 5.1 77 5.05 53 4.3 0.23 1.25 (0.86–1.81)
Non-conserved 85 7.1 16 4.8 101 6.6 65 5.2 0.072 1.34 (0.96–1.87)
AH 8.1+Non-conserved 145 12.1 33 9.9 178 11.7 118 9.5 0.027 1.32 (1.02–1.70)
TOTAL NUMBER 1194 332
1 1526
1 1248
% are referred to the total number of haplotypes analysed in each group (last row).
AH 18.2 includes haplotypes carrying DRB1*03:01, DQB1*02:01, TNF -376A, TNF a1b5 and B*18. AH 8.1 includes haplotypes carrying DRB1*03:01, DQB1*02:01, TNF -308A,
TNF a2b3 and B*8. Haplotypes with all the remaining allelic combinations in those loci or markers are included as ‘‘non-conserved’’ haplotypes.
1Excluding the HLA-DRB1*15:01-containing haplotypes.
doi:10.1371/journal.pone.0031018.t001
Table 2. Frequency of the different DRB1*03:01-containing haplotypes in multiple sclerosis (MS) patients stratified by the
presence/abscence of oligoclonal IgM against myelin lipids (M+/M2) and in controls; and comparisons between groups.
MS PATIENTS
CONTROLS
M+ vs. M2 M+ vs. Controls M2 vs. Controls
M+ M2 p, OR (95%CI) p, OR (95%CI) p, OR (95%CI)
n% n% n %
DRB1*03:01
All 19 20.4 20 15.2 167 13.4 0.30, 1.44 (0.68–3.04) 0.058, 1.66 (0.94–2.90) 0.57, 1.16 (0.68–1.96)
AH 18.2 10 10.8 3 2.3 49 3.9 0.0088, 5.05 (1.23–29.24) 0.0055, 2.98 (1.36–6.39) 0.27, 0.59 (0.12–1.88)
AH 8.1 2 2.2 6 4.5 53 4.3 0.48, 0.50 (0.05–2.93) 0.55, 0.54 (0.06–2.17) 0.84, 1.09 (0.38–2.62)
Non-conserved 7 7.5 11 8.3 65 5.2 0.94, 0.96 (0.32–2.84) 0.19, 1.57 (0.59–3.60) 0.15, 1.63 (0.79–3.30)
AH 8.1+ Non-
conserved
9 9.7 17 12.9 118 9.5 0.61, 0.80 (0.31–2.03) 0.77, 1.11 (0.51–2.37) 0.23, 1.39 (0.78–2.46)
TOTAL NUMBER 93 132 1248
% are referred to the total number of haplotypes analysed in each group (last row).
AH 18.2 includes haplotypes carrying DRB1*03:01, DQB1*02:01, TNF -376A, TNF a1b5 and B*18. AH 8.1 includes haplotypes carrying DRB1*03:01, DQB1*02:01, TNF -308A,
TNF a2b3 and B*8. Haplotypes with all the remaining allelic combinations in those loci or markers are included as ‘‘non-conserved’’ haplotypes.
HLA-DRB1*15:01-containing haplotypes in MS patients were removed from the analysis.
doi:10.1371/journal.pone.0031018.t002
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percentage of M+ individuals among MS patients (around 40%),
makes that a susceptibility signal emerges also when considering
the overall MS patients independently of the presence/absence of
OCMB, although, obviously, causing an apparently lower risk.
This finding could explain the heterogeneous results regarding
HLA-DRB1*03 previously published. The percentage of AH 18.2
from the total HLA-DRB1*03 and the percentage of M+
individuals from the total MS patients will determine obtaining
a significant result. Moreover, the situation is probably more
complicated. Although statistical power limitations preclude a
conclusive interpretation of data regarding DRB1*03 haplotypes
others than 18.2, it seems that at least the non-conserved ones
influence disease development, although with a lower risk.
A different disease risk caused by the diverse DRB1*03-bearing
haplotypes has also been described in type 1 diabetes (T1D).
Baschal et al. reported the highest risk for the AH 18.2 and the
lowest risk for AH 8.1 [15]. More powered studies are required to
establish whether the AH 8.1 contributes to MS development. Our
data discard a strong effect for AH 8.1, as the one observed for AH
18.2, and, consequently, our sample size could not be enough to
obtain a significant result, although it might exist. The reported
association between DRB1*03:01 and MS risk in some Northern-
European populations [5], where the most common DRB1*03:01
haplotype is the AH 8.1, suggests that it could be contributing to
disease risk.
The previously described association of MS and OCMB with
TNF -376A seems to be due to the presence of this allele on the
AH 18.2 and therefore, to the linkage disequilibrium with the
causal variant/s present on that haplotype.
The association of AH18.2 and intrathecal anti-lipid IgM
synthesis could have important clinical implications. The presence
of those antibodies has been related to development of an
aggressive MS [14,16,17] and it has been described that those
patients could benefit of an early immunomodulatory treatment
[18]. Moreover, a better response to treatment with interferon-
beta has been described for patients lacking OCMB [19].
Therefore, MS patients carrying the AH18.2 deserve special
attention. It must be underlined that only 4% of patients with that
haplotype do not have intrathecal IgM. However, further research
is needed since AH 18.2 appears in 12% of M+ individuals and
additional factors must therefore contribute to IgM production.
MS is characterized by an extensive heterogeneity in terms of
clinical features, pathogenesis or responsiveness to treatments. The
mechanism underlying those differences is still uncovered, but a
genetic contribution must exist. Therefore, the analysis of the
overall MS patients can miss genetic variants relevant for certain
groups, as it is proved in our work. On the contrary, the study of
well-characterized subgroups seems to be a good strategy to
further increase the number of genes involved in MS susceptibility,
contributing to elucidate part of the ‘‘missing heritability’’ [20].
Despite the great advances in the genetics of MS, more than 50%
of the disease heritability remains unsolved. Our results show an
increase of the odds ratio as we define the best marker of the causal
variant/s and the specific affected subgroup. Thus, from an initial
OR=1.52 conferred by DRB1*03:01, we moved to OR=1.94
caused by the specific AH 18.2 to MS overall and to OR=2.98
when we consider specifically M+ patients. Note that this effect is
similar to the one caused by DRB1*15:01, the main risk factor to
MS susceptibility. A parallel situation is expected for genetic
variants affecting only subgroups of patients. According to our
data, promising results can be expected from studying more
homogeneous groups of MS patients.
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